Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
PDXHCI002 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.9869 | -0.0453 | -0.0479 | 0.0000 | Inf | -4.5815 |
PDXHCI002 | Bleomycin | Radiation | Misc | 1.1636 | -0.1199 | 0.2715 | -0.0373 | 0.9659 | 2.0671 | 0.9892 |
PDXHCI002 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.20621 | 0.2290 | 0.2366 | -0.0367 | 1.3099 | 0.11357 | 0.97533 |
PDXHCI002 | Etoposide | Topo II | Chemotherapy | 0.18199 | -0.1795 | 0.4902 | -0.0311 | 1.1589 | 0.23962 | 0.98993 |
PDXHCI002 | Cisplatin | Chemo | Chemotherapy | 1.7306 | -0.0985 | 0.2044 | -0.0257 | 1.2874 | 2.4053 | 0.98631 |
CAL-51 | Palbociclib | CDK4/6 | Cell cycle | 0.37241 | 0.3607 | 0.2498 | -0.0215 | 0.8353 | 0.084749 | 0.99265 |
MDA-MB-134-VI | Palbociclib | CDK4/6 | Cell cycle | 0.0092186 | 0.1787 | 0.5339 | -0.0169 | 1.7301 | 0.0071324 | 0.98727 |
HCC1500 | Bleomycin | Radiation | Misc | 2.3381 | 0.1740 | 0.1688 | -0.0166 | 1.0174 | 2.4596 | 0.98358 |
HCC1500 | Etoposide | Topo II | Chemotherapy | 1.4287 | -0.0766 | 0.2499 | -0.0148 | 1.3319 | 1.7871 | 0.95725 |
PDXHCI002 | Palbociclib | CDK4/6 | Cell cycle | 0.12955 | 0.2766 | 0.2793 | -0.0122 | 1.1851 | 0.053617 | 0.97783 |
PDXHCI002 | Ipatasertib | AKT | PI3K/mTOR | Inf | 1.0500 | -0.0488 | -0.0112 | 0.0000 | Inf | -59.6281 |
HCC1500 | Cisplatin | Chemo | Chemotherapy | 3.4531 | 0.2076 | 0.1210 | -0.0094 | 5.0000 | 3.1071 | 0.92762 |
HCC1500 | Abemaciclib | CDK4/6 | Cell cycle | 0.53346 | 0.2196 | 0.3452 | -0.0085 | 0.4860 | 0.1477 | 0.84102 |
HCC1954 | Cabozantinib | VEGFR2/MET | RTK | 10.9106 | 0.6390 | -0.0135 | -0.0074 | 5.0000 | 13.0234 | 0.87916 |
MDA-MB-134-VI | Cisplatin | Chemo | Chemotherapy | 10.3229 | 0.5019 | 0.0719 | -0.0064 | 0.7594 | 36.1235 | 0.92643 |
HCC1954 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.8349 | -0.0093 | -0.0064 | 1.3800 | 7.2097 | 0.65841 |
MDA-MB-134-VI | Cabozantinib | VEGFR2/MET | RTK | 10.9194 | 0.6362 | -0.0167 | -0.0063 | 5.0000 | 12.725 | 0.88168 |
CAL-120 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 1.0198 | -0.0168 | -0.0059 | 0.0000 | Inf | -0.45144 |
HCC1419 | Palbociclib | CDK4/6 | Cell cycle | 0.48725 | 0.4414 | 0.2239 | -0.0054 | 1.2398 | 0.053717 | 0.97241 |
CAL-120 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.5275 | 0.4163 | -0.0050 | 0.1797 | 1.1993e-05 | 0.81569 |
HCC1954 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9607 | -0.0374 | -0.0050 | 0.0000 | Inf | -1.0282 |
HCC1954 | Palbociclib | CDK4/6 | Cell cycle | Inf | 0.5256 | 0.1839 | -0.0048 | 1.2148 | 0.056374 | 0.97285 |
MCF 10A | Palbociclib | CDK4/6 | Cell cycle | 1.9503 | 0.4544 | 0.1883 | -0.0047 | 0.6492 | 0.23713 | 0.99244 |
CAL-85-1 | Ipatasertib | AKT | PI3K/mTOR | Inf | 0.4714 | 0.1662 | -0.0047 | 1.3900 | 0.27338 | 0.96561 |
PDXHCI002 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.8545 | -0.0204 | -0.0045 | 5.0000 | 4.5889 | 0.61889 |